Miller, W., and S. Rollnick. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford Press, 1991. This book describes a nonauthoritarian approach to helping people struggling with addictive behaviors overcome their ambivalence and get "unstuck." The authors review the conceptual and research background of motivational interviewing, provide practical introductions to using the approach, and bring together contributions from international experts describing their use of the model with a broad range of populations. Minkoff, K., and R. Drake. Dual Diagnosis of Major Mental Illness and Substance Disorder. Indianapolis, Ind.: Jossey-Bass, 1991. Significant advances have been made in both the conceptualization and the development of innovative models providing integrated assessment and treatment for people with dual diagnoses. The purpose of this volume is to provide information about the current theories and clinical interventions and to describe innovative treatment programs. Prochaska, J. O., C. C. DiClemente, and J. C. Norcross. "In Search of How People Change: Applications to Addictive Behaviors." American Psychologist 47, no. 9 1992 ; : 11021114. This seminal article describes the transtheoretical model of change Stages of Change ; , an idea that describes how people change or modify addictive behaviors. The authors describe five stages in the process: precontemplation, contemplation, preparation, action, and maintenance. Robbins, R., A. Tafe, and M. Argeriou. Alcohol and Drug Free Housing Guide. Alcoholism and Drug Abuse Association and Stabilization Services Project, 2000. This guide is intended to assist individuals in recovery to achieve their goal of sobriety. The authors suggest that adequate preparation for securing alcohol- and drug-free housing increases the likelihood of success. This manual provides information and advice to those seeking sober housing and serves as a teaching tool for substance abuse workers. Roberts, L., and T. Eckman. Overcoming Addictions: Skills Training for People with Schizophrenia. New York: W. W. Norton and Company, 1999. This book helps staff members teach groups of individuals with schizophrenia how to avoid drugs and alcohol, recognize signs of relapse, and build healthy habits and pleasures into their daily routines. The book emphasizes an attitude of acceptance, tolerance, and optimism toward clients. Each chapter includes suggested scripts for use in each training session. Includes a glossary, numerous forms, and other materials for use in the program. Stevens, P., and R. Smith. Substance Abuse Counseling: Theory and Practice. Upper Saddle River, N.J.: Merrill Prentice Hall, 2001. A good resource for substance-abuse counselors seeking information on the stages of counseling-- from assessment and diagnosis through relapse prevention. Tims, F J. Platt, and C. Leukefeld. Relapse and Recovery in Addictions. New Haven, Conn.: Yale University ., Press, 2001. This important volume brings together the major perspectives on addiction, treatment, and recovery, along with current research findings. The contributors explore a wide range of topics, including craving and emotional factors in relapse, pharmacotherapies, adolescent treatment, outcome research, clients in the criminal justice system, the self-help movement, and health services issues such as managed care and linkages to other systems and lomefloxacin.
Martha K. Spradley, MA * , and Richard L. Jantz, PhD, University of Tennessee, Department of Anthropology, 250 South Stadium Hall, Knoxville, TN 37996; David M. Glassmann, PhD, University of Southern Indiana, School of Liberal Arts, 8600 University Boulevard, Evansville, IN 47712-3596; and Alan G. Robinson, MSc, Fundacion de Antropologia Forense de Guatemala, Avenida Simon Canas 10-64 Zona 2, Ciudad de Guatemala, Guatemala City, 01002, Guatemala The goal of this presentation is to present the biological variation that exists among Hispanic Spanish-speaking ; peoples of the Americas and how this variation allows for the development of better standards in ancestry identification. The purpose of this paper is to demonstrate the biological variation that exists among Hispanic Spanish-speaking ; peoples of the Americas. This paper will also attempt to show that craniometric data from different geographic areas in Latin America and Mexico could aid in the determination of the geographic origin of unknown individuals identified as Hispanic. Additionally, this paper will explore postcranial variation of Hispanic groups when compared to American Blacks and Whites. The impact of this research can aid in the development of better craniometric standards for use in ancestry identification on an international level. For example, FORDISC 3.0 will have more appropriate samples for use in Latin America and other parts of the world. The determination of ancestry or group affiliation is one of the primary factors in a forensic anthropological analysis. Craniometric data is commonly used as a means of ancestry determination. However, sample specific standards may not always be readily available for a particular group. In the United States, "Hispanic" refers to individuals originating from Mexico, Puerto Rico, Cuba, South or Central America, or other Hispanic Latino origin U.S. Census Bureau 2003 ; and therefore does not have precise genetic meaning. In general, Hispanics are hybrid populations composed of various African, Native American and European genetic backgrounds. Caribbean Hispanics may have large African components, while Mexican Hispanics may have large Native American components. For example, Ross et al. 2004, using geometric morphometric methods, found Cuban Americans nearer to American Blacks, indicating the term Hispanic as too broad. When analyzing biological variation from skeletal metrics, a commonly used method is biological distance or Mahalanobis D2, a measure of population divergence based on polygenic traits Buikstra et al. 1990 ; . Samples used in this analysis are Guatemalans, Argentineans, American Hispanics and American Whites. All samples are modern and forensic in nature. The D2 distances among all groups are all significant at the .001 level, indicating that group centroids are significantly different. The D2 distance matrix indicates that the smallest distances, therefore the most similarities are found between American White and American Hispanic females, followed by males from the same groups. Argentinean males are more similar to American Hispanic males and furthest from. Any of the available agonist opioids can be selected for the opioid-naive patient without major organ failure. Short-half-life opioids morphine, hydromorphone, oxycodone, or oxymorphone ; are generally favoured because they are easier to titrate than the long-half-life drugs, which require a longer period to approach steady state plasma concentrations. Among the short-half-life opioids, the range of available formulations often influences specific drug selection. For ambulatory patients who are able to tolerate oral opioids, morphine sulphate is generally preferred since it has a short half-life and is easy to titrate in its normal-release form; it is also available as sustained-release preparations that allow 12- and 24-h dosing intervals. The long-half-life opioids methadone and levorphanol are not usually considered for first-line therapy because they can be difficult to titrate and present challenging management problems if delayed toxicity develops as plasma concentrations gradually rise following dose increments. For the reasons previously described, the use of pethidine, dextromoramide, and dipipanone for the management of cancer pain is discouraged. When the oral route of opioid administration is contraindicated, the available routes of administration may become an important consideration in opioid selection. Fentanyl and buprenorphine are available for administration by the transdermal route. Although most of the full agonist drugs are well absorbed by subcutaneous infusion, some like morphine tartrate, hydromorphone, and diamorphine ; are more suitable by virtue of their high solubility and low irritability. Methadone and fentanyl may produce significant local irritation when administered by the subcutaneous route. For cultural and aesthetic reasons, the subcutaneous route is often preferred to rectal administration. Subcutaneous infusion may be also preferable in patients at the end of life because it is less disruptive than using intermittent analgesic suppositories when nursing a sick patient and lomotil. Mucopolysaccharidoses MPS ; are a group of genetic diseases caused by the lack of one of the lysosomal enzymes in charge of a specific stage of glycosaminoglycan GAG ; degradation. Mucopolysaccharidosis II MPS II or Hunter syndrome ; is X-linked, and results from the deficiency of iduronate sulfatase IDS ; , with consequent increase in the urinary concentration of dermatan sulfate and heparan sulfate.1 According to international studies, MPS II is estimated to affect 1 in every 68, 000 to 1 in every 320, 000 live births.2, 3 Although accurate data are not available on the incidence of MPS in Brazil, MPS II seems to be one of the most frequently diagnosed types of this disease in Brazil. At the Laboratory of Inborn Errors of Metabolism of the Division of Medical Genetics of Hospital de Clnicas de Porto Alegre, a referral laboratory for the diagnosis of MPS in Brazil, 104 Brazilian MPS patients were diagnosed between April 2004 and September 2005. The following types were diagnosed: MPS I 33 cases ; , MPS II.

They have a mandate to switch a lot of homes over to High Efficiency heating equipment over the next five years and would like the help of HVCI and RHWHA to ensure that this equipment is installed as it is intended. We continue work on development of a joint industry approach to accomplish this end. Int.Cl.7 G06T11 00. Method of simulating the creation of an artist`s drawing or painting, and device for accomplishing same. Foto Fantasy, Inc and lortab and levorphanol. Aminoromission any direct effect on patient morbidity, however, may have affected patient care in a minor way. If a minor deficiencyisidentified, confirmedinwriting ; orwritten counselling via the Ambulance Call Review Process. 0. 1 ml the cell suspenof a standard microtiter was shown of RPMI also placed in Table medium. in 1 and lotronex. 14. Sharpe, I. A., Palant, E., Kaye, D. M., Adams, D. J., and Lewis, R. J. 2003 ; J. Biol. Chem. submitted 15. Paczkowski, F. A., Bryan-Lluka, L. J., Przgen, P., Brss, M., and Bnisch, H. 1999 ; J. Pharmacol. Exp. Ther. 290, 761-767 16. Sucic, S., and Bryan-Lluka, L. J. 2002 ; Brain Res. Mol. Brain Res. 108, 40-50 17. Lowry, O., Rosebrough, N., Farr, A., and Randall, R. 1951 ; J. Biol. Chem. 193, 265-275 18. Cheng, Y., and Prusoff, W. 1973 ; Biochem. Pharmacol. 22, 3099-3108 19. Graefe, K.-H., and Bnisch, H. 1988 ; In: Trendelenburg, U., and Weiner, N., Eds. Handbook of Experimental Pharmacology, 90. Catecholamines, Vol. I, Springer-Verlag, Berlin Heidelberg New York. pp. 193-245. 20. Buck, K. J., and Amara, S. G. 1994 ; Proc. Natl. Acad. Sci. USA 91, 12584-12588 21. Syringas, M., Janin, F., Mezghanni, S., Giros, B., Costentin, J., and Bonnet, J.-J. 2000 ; Mol. Pharmacol. 58, 1404-1411 22. Harder, R., and Bnisch, H. 1985 ; J. Neurochem. 45, 1154-1162 23. Bnisch, H. 1998 ; In: Amara, S. G., Ed. Methods in Enzymology, Volume 296. Neurotransmitter Transporters, Plenum Press, New York. pp. 259-278. 24. DeFelice, L. J., Adams, S. V., and Ypey, D. L. 2001 ; Biosystems 62, 57-66 25. Pacholczyk, T., Blakely, R. D., and Amara, S. G. 1991 ; Nature 350, 350-353 26. Roubert, C., Sagn, C., Kapsimali, M., Vernier, P., Bourrat, F., and Giros, B. 2001 ; Mol. Pharmacol. 60, 462-473.
This paper has been divided into four sections. The first section The Political Economy of Agricultural Protection ; stresses the diversity of pressures in favor of and against agricultural trade liberalization. The second section Market Access for Agricultural Products in the Western Hemisphere and in the European Union ; employs various methods to measure the level of tariff protection in agricultural and non-agricultural products. This section introduces new indicators to evaluate tariff protection in bilateral and regional integration agreements. The third section Overview of Domestic and Export Agricultural Subsidies in the World ; presents different sources of data and methodologies available to measure subsidies and compares their results according to different criteria. The fourth section Identification of Sensitive Agricultural Products ; displays a list of the most sensitive agricultural products in the WH based on various criteria factors: level of tariffs, use of tariff rate quotas, Sanitary and Phytosanitary measures SPS ; and Technical Barriers to Trade TBT ; notifications, subsidies and others. Finally, the last section Conclusions and Policy Recommendations ; presents provides policymakers with special recommendations, based on the findings of this research paper.

Executive Committee Dr. Giuseppe Vita Chairman ; Norbert Deutschmann Dr. Reiner Hagemann Sabine Spke Audit Committee Dr. Karl-Hermann Baumann Chairman ; Norbert Deutschmann Dr. Giuseppe Vita Heinz-Georg Webers Nomination and Compensation Committee Dr. Giuseppe Vita Chairman ; Norbert Deutschmann Dr. Reiner Hagemann Heinz-Georg Webers Research and Development Committee Dr. Giuseppe Vita Chairman ; Prof. Dr. Piet Borst Norbert Deutschmann Prof. John A. Dormandy Dr. Hans-Peter Niendorf Dr. Ulrich Sommer Committee in accordance with section 27 3 ; of the German Co-Determination Act MitbestG ; Hans-Georg Bleeck Norbert Deutschmann Dr. Reiner Hagemann Dr. Giuseppe Vita.
Boiled water is safest. Must be heated to a bubbling boil for one minute. Water, even in a 5-star American or European owned luxury hotel, is never assuredly safe. This includes the water in your room or restaurant pitcher which they vehemently insist has been boiled. If available, bottled water carbonated or uncarbonated ; that has a tamper proof top and that you open yourself or is opened in front of you ; is almost always safe. If you have access to an electrical outlet or cooking facilities you can boil water yourself. Immersible electric coils are compact to pack. Carbonated soft drinks open them yourself ; , beer, hot tea or hot coffee are generally safe. Containers or glasses may be dirty. Drink from the bottle after you have wiped the opening ; . Avoid fruit juices not directly from the can or box. They may be diluted with contaminated water. If you are going out for the day where facilities are unknown or inadequate, carry some drinking water with you. Ice 1 cube in one drink can destroy a vacation ; is never safe. Purification tablets and filters work well but are not as effective as boiling. Electronic claims submission to MedNet Payers Connect to our payers electronically for quick and efficient processing of MedNet participating enrollee claims. MedNet has direct and indirect electronic connectivity with the following payers for the purposes of repricing participating member claims: Benefit Plan Management, Inc. P.O. Box 536 Rockland, MA 02370 Payer ID: #37222 Clearinghouse s ; : ProxyMed, Embdeon Comprehensive Benefits Administrator, Inc. P.O Box 2365 South Burlington, VT 05407 Payer ID: #03036 Clearinghouse s ; : Interactive Payer Network Employee Benefit Plan Administrators, Inc. P.O. Box 2000 Exeter, NH 03833 Payer ID: #03036 Clearinghouse s ; : Interactive Payer Network Health Plans, Inc. P.O. Box 5199 Westborough, MA 01581 Payer ID: #44273 Clearinghouse s ; : Embdeon Patient Advocates, LLC P.O. Box 1959 Gray, ME 04039 Payer ID: #10525 Clearinghouse s ; : Embdeon United Healthcare P.O. Box 740800 Atlanta, GA 30374 Payer ID: #87726 Clearinghouse s ; : Embdeon For questions or more information about EDI connectivity with MedNet's participating payers, contact Robert Hillman at 207 ; 773-5116, ext 130. MedNet welcomes its newest participating providers! Take a moment to visit our website and check your listing online at mainemednet . Notify us immediately if your listing requires updating or correction. Additionally, please notify MedNet 30 days in advance if any of the following changes occur in your practice: Practitioners joining or terminating from the practice Changes in information regarding mailing, billing, or practice addresses Changes in telephone or fax numbers Change in your tax identification number Practice closes to new patients All notifications should be sent to: Medical Network, Inc. Provider Relations Department PO Box 15253 Portland, ME 04112 Or by fax: 207-773-1739 Please note: changes updates communicated to MedNet are not forwarded to Harvard Pilgrim Health Care, which must be notified directly . Please keep Harvard Pilgrim Health Care informed by sending notifications to: Harvard Pilgrim Health Care Maine Provider Relations Department, 1600 Crown Colony Dr., Quincy, MA 02169 or by fax: 866-884-3843 or by email: office provider relations hphc and lexiva.

MATERIALS AND METHODS Materials. [3H]Etorphine 30 Ci mmol; 1 Ci 37 GBq ; , [3H]ethylketocyclazocine EKC ; 45 Ci mmol ; , and U50, 488H Upjohn ; were donated by the National Institute on Drug Abuse Rockville, MD levorphanol was a gift from Hoffman-La Roche. 3H-labeled [D-Ala2, D-Leu5]enkephalin DADLE ; 36 Ci mmol ; , 3H-labeled [D-Ala2, NMePhe4, Gly5ollenkephalin DAGO ; 60 Ci mmol ; , [3-iodotyrosyl-1251, Leu5]enkephalin 2000 Ci mmol ; , and [3H]a-bungarotoxin 83 Ci mmol ; were purchased from Amersham. - ; -[3H]nicotine 63 Ci mmol ; and ; -[3H]nicotine 51 Ci mmol ; were purchased from DuPont NEN. Commercial sources for the other chemicals were as follows: DAGO, DADLE, [DPen2, D-Pen5]enkephalin DPDPE ; , Peninsula Laboratories morphine sulfate Mallinckrodt - ; -nicotine ditartrate, hexamethonium bromide, decamethonium bromide, mecamylamine hydrochloride, a-bungarotoxin, atropine, naloxone hydrochloride Sigma ; . Cell Lines and Growth Assays. Previously characterized SCLC and non-SCLC cell lines were grown in RPMI 1640 medium GIBCO ; supplemented with 10o fetal calf serum as described 14, 15 ; . That cells were free of mycoplasma contamination was indicated by a molecular hybridization assay used according to the vendor's instructions GenProbe, San Diego, CA ; . A semiautomated colorimetric assay 16 ; , based on the ability of live cells to reduce a tetrazoliumbased compound, 3- 4, 5-dimethylthiazol-2-yl ; -2, 5-diphenyl tetrazolium bromide MTT, Sigma ; to give a purple-colored product, was used to measure growth of the cells spectrometrically in the presence of various agonists and antagoAbbreviations: DAGO [D-Ala2, NMePhe4, Gly5-ol]enkephalin; Pen, penicillamine; DPDPE, DADLE.
To determine whether the gene encoding the recently identified heparin-binding epidermal growth factorlike growth factor HB-EGF ; , a potent smooth muscle cell SMC ; mitogen of macrophage origin, is transcribed and regulated in vascular SMC, we isolated cDNA clones encoding rat HB-EGF from a macrophage library. Using the rat HB-EGF cDNA as a probe for RNA blot analysis, we detected low levels of HB-EGF M mRNA in rat aortic SMC in culture. However, 20 n TPA ; and lo-` M angiotensin I1 AII ; induced a marked increase in HB-EGF mRNA levels in rat aortic SMC 11- and 4.6-fold, respectively ; that was both dose- and timedependent. In response to TPA and AII, HB-EGF mRNA levels increased rapidly, peaked at 2 h, and returned to base line at 7 h. This effect of AI1 on HBEGF induction was specific, as evidenced by the fact that it could be completely blocked by the AI1 antagonist saralasin. This is the first demonstration that HB-EGF is transcribed and regulated in SMC. The inducible transcription of this potent SMC mitogen gene invascular SMC suggests that HB-EGF may have an important autocrine role in the proliferation of SMC in vascular diseases such as atherosclerosis and hypertension. Morphine equivalents ME ; displayed Conversion factor choice Conversions for: transdermal fentanyl transmucosal fentanyl methadone hydrocodone levorphanol combination products meperidine propoxyphene Convert to methadone method Alternate routes IT, EP, etc. ; addressed Available formulations addressed List of opioids available for performing calculations Equianalgesic table displayed Acute vs chronic dosing for morphine methadone Interface Dose entry Hopkins Parenteral ME No choice Yes No Yes No Yes No Yes No No choice Oral, parenteral, transdermal, only No All-in-one drop down list No No No, but discussed in User's Manual Tap in using application's virtual buttons Large: minimal scrolling GlobalRPh Oral ME User may edit table Yes No Yes Yes No No Yes No Choose 1 of 2 methods Oral, parenteral, transdermal, only No All-in-one drop down list Yes Yes Yes Cynergy Group Oral ME No choice Yes Yes Yes Yes Yes Yes Convert from, only Convert from, only No choice All Yes When route selected, only appropriate drugs displayed No No No, but discussed in instructions. The endocrine system accomplishes these tasks via a network of glands and organs that produce, store and secrete certain hormones. Society for Endocrinology; The Hormone Foundation. Pooled asset funds are carried at the lower of cost or market and include the Company's interest in various funds which invest in common and preferred stocks, bonds, and money market funds. Earnings on these investments included under the caption "Other Income" amounted to 9, 000 in 1995, 2, 000 in 1994 and 5, 000 ; in 1993. At March 31, 1995 and 1994 the carrying amounts of these investments approximated fair value. Cash surrender value represents insurance policies on certain officers and key employees and the value of a split dollar life insurance arrangement with the estate of the former Chairman and Chief Executive Officer of the Company see note P ; . Other investments are comprised principally of equity investments in non-publically traded entities. Such investments are accounted for under the cost method. Prior to December 21, 1994 the Company's interest in a captive insurance company was accounted for using the equity method of accounting see note B ; . Earnings from this investment included under the caption "Other Income" amounted to 4, 000 in 1995 prior to acquisition, 7, 000 in 1994 and 0, 000 in 1993. I. Other Current Liabilities Other current liabilities includes payroll and employee benefit plan accruals which amounted to , 103, 000 at March 31, 1995 and , 388, 000 at March 31, 1994, accruals for Medicaid reimbursements of , 640, 000 at March 31, 1995 and , 479, 000 at March 31, 1994 and deferred revenue related to a distribution agreement see note K ; of , 500, 000 at March 31, 1995. J. Long-Term Obligations Long-term obligations represent accruals for post-retirement compensation pursuant to agreements with certain key employees and directors. Under these agreements, benefits are to be paid over periods of 10 to years commencing at retirement. K. Distribution Agreement On October 10, 1994 the Company entered into a distribution agreement with STC Pharmaceuticals, Inc. STC ; , a wholly owned subsidiary of Eli Lilly and Company Lilly ; . Under the terms of the agreement the Company is distributing a generic form of Lilly's oral antibiotic Ceclor R ; on behalf of STC. The Company is being paid a fixed monthly fee for distributing the product. Upon certain events, as defined in the agreement, the fixed monthly fee will convert to a variable amount predicated upon STC's net sales of the product. Revenues and gross profits resulting from this agreement did not have a material impact on operations. Poctacov software, magnetick nebo optick nosice zvukovch nebo obrazovch zznam nahran i nenahran, nosice dat optick, nosice dat magnetick, nosice zvukovch nahrvek, operacn systmy nahran programy ; , pstroje pro zznam, penos nebo reprodukci zvuku ci obrazu, antny, vyslace, software na magnetickch nosicch, videokazety a audiokazety nahran i nenahran, gramofonov desky, audiovizuln programy na nosicch zznam, a to i v digitln podob, kompaktn disky audio-video ; , videodisky, informace a zznamy v elektronick podob na nosicch zznam; 38 ; telekomunikace, rozhlasov vysln, vysln kabelov televize, komunikace pomoc mobilnch telefon, komunikace pomoc poctacovch terminl, pensen pomoc satelitnch druzic, agentury tiskov, pronjem zazen pro penos informac, penos zprv a obrazovch informac pomoc poctace, penos faxem, pjcovn telekomunikacnch zazen, telefonick sluzby, televizn vysln, telexov sluzby, vysln radiov; 41 ; digitln zpracovn obrazu, elektronick publikovn, klubov sluzby, konference, organizovn kulturnch nebo vzdlvacch vstav, organizovn pedstaven, poskytovn on-line elektronickch publikac, provozovn her on-line, rozhlasov a televizn vysln vroba ; , rozhlasov a televizn pijmace pronjem ; , skolen, televizn programy vroba rozhlasovch a televiznch program ; , televizn zbava, vydvn elektronickch knih a casopis on-line, vchovn, vzdlvac a zbavn cinnost, organizovn kulturnch, vzdlvacch a zbavnch akc, agenturn cinnost v oblasti kultury a vzdlvn, organizace zbavnch poad a soutz, obstaravatelsk a zprostedkovatelsk cinnost v oblasti kultury a zbavy, informace o moznostech zbavy a vzdlvn, rozhlasov zbava, diskotky, ziv vystoupen, estrdy, karaoke, zpravodajsk sluzby, agentury spadajc do tto tdy, organizovn a veden semin a konferenc, sluzby nahrvacho studia, pronjem zvukovho nahrvacho studia, pronjem audio nahrvek. Barevn STAMFORD MANAGING a.s., Kopernkova 794 6, Praha 2, 12000, CZ Mgr. Olga Sedlckov, Nad Petruskou 1, Praha 2, 12000. [2] An, J., Totrov, M., and Abagyan, R., Pocketome via comprehensive identication and classication of ligand binding envelopes, Mol. Cell Proteomics, 4 6 ; : 752 761, 2005. [3] Ashburn, T.T. and Thor, K.B., Drug repositioning: Identifying and developing new uses for existing drugs, Nat. Rev. Drug Discov., 3 8 ; : 673 683, 2004. [4] Bolen, J.B. and Brugge, J.S., Leukocyte protein tyrosine kinases: Potential targets for drug discovery, Annu. Rev. Immunol, 15: 371 404, [5] Bourne, P.E., Addess, K.J., Bluhm, W.F., Chen, L., Deshpande, N., Feng, Z., Fleri, W., Green, R., Merino-Ott, J.C., Townsend-Merino, W., Weissig, H., Westbrook, J., and Berman, H.M., The distribution and query systems of the RCSB Protein Data Bank, Nucleic Acids Res., 32: D223 D225, 2004. [6] Bursulaya, B.D., Totrov, M., Abagyan, R., and Brooks, C.L. 3rd., Comparative study of several algorithms for exible ligand docking, J. Comput. Aided Mol. Des., 17 11 ; : 755 763, 2003. [7] Cavasotto, C.N., Ortiz, M.A., Abagyan, R.A., Piedrata, F.J., In silico identication of novel EGFR inhibitors with antiproliferative activity against cancer cells, Bioorg. Med. Chem. Lett., 16 7 ; : 1969 1974, 2006. [8] Chen, H., Lyne, P.D., Giordanetto, F., Lovell, T., and Li, J., On evaluating molecular-docking methods for pose prediction and enrichment factors, J. Chem. Inf. Model., 46 1 ; : 401 415, 2006. [9] Chen, Y.Z. and Zhi, D.G., Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule, Proteins, 43 2 ; : 217 226, 2001. [10] Chien, D.S., Sandri, R.B., and Tang-Liu, D.S., Systemic pharmacokinetics of acitretin, etretinate, isotretinoin, and acetylenic retinoids in guinea pigs and obese rats, Drug Metab. Dispos., 20 2 ; : 211 217, 1992. [11] Frantz, S., Drug discovery: Playing dirty, Nature, 437 7061 ; : 942 943, 2005. [12] Fukunishi, Y., Mikami, Y., Kubota, S., and Nakamura, H., Multiple target screening method for robust and accurate in silico ligand screening, J. Mol. Graph. Model., 25 1 ; : 61 70, 2006. [13] Jorgensen, W.L., The many roles of computation in drug discovery, Science, 303 5665 ; : 1813 1818. 2004. [14] Kola, I. and Landis, J., Can the pharmaceutical industry reduce attrition rates, Nat. Discov., 3 8 ; : 711 715, 2004.

Spiriva With our successful track record in respiratory medicines, we are well-placed to deliver new products to benefit patients with chronic obstructive pulmonary disease COPD ; . Our best example at present is spiriva, a novel, once-daily inhaled M3antagonist for the maintenance treatment of COPD, discovered and developed by our company. spiriva performed extremely well from its initial launch and far exceeded our ambitious market expectations in its first half year on the market. Given this take-off, we expect spiriva to capture a lead position in the respiratory market in the not too distant future and attain the blockbuster status foreseen for it once launched in all major markets.
The 55th Annual Meeting of the American Academy of Neurology was held in Honolulu, Hawaii from March 29 to April 5, 2003. Over 200 talks and presentations on a wide range of MS studies were included. Some of the highlights are summarized below; the full list of speakers' abstracts [144 pages] is available at the drop-in centre or at : aan professionals Simvastatin [Zocor, ] a cholesterol-lowering drug, may also treat RRMS according to US researchers. A 28-patient 2-year trial found a 43% decrease in the number of active lesions and a 41% decrease in the volume of brain tissue affected. Of the 28 patients, 2 had an increase in lesions and 23 showed a decrease; 3 showed no change. Zocor is taken orally, not by injection. The next stage of studies may start in a few months. 31 03 Mitoxantrone may prevent disease progression in PPMS, especially those with an EDSS less than 6, say French researchers who treated 64 PPMS patients with mitoxantrone, either monthly for 6 months, or every 3 months for up to 24 months. Between baseline and the second year, 34% deteriorated and 24% had a one-point improvement in their EDSS. The results demonstrate that mitoxantrone favourably alters disease progression and warrant the launch of a phase III trial in PPMS patients. 04 03 8-week US trial of the morphine-like medication levorphanol for treatment of chronic pain due to neuropathic pain found that its ability to reduce pain was comparable to that of tricyclic antidepressants and gabapentin. The high-dose group averaged a 36% decrease in their pain, much greater pain reduction than a lower-dose regimen. The patients returned to pre-study pain levels after the treatment. Patients did not become tolerant of the opiod drug. 26 03 Neutralizing antibodies can appear early during the course of interferon-beta MS treatment and reduce or abolish the clinical efficacy of interferon-beta. Three studies of Copaxone showed that all patients treated with Copaxone develop Copaxone-reactive antibodies. These antibodies were not found to be neutralizing and did not interfere with the ability of the drug to work, nor did they induce any adverse reactions. 27 03 study reviewing the pregnancy outcomes in women treated with Copaxone through 21 global clinical trials and postmarketing surveillance data indicates that in women with RRMS, the risk of congenital anomalies or spontaneous abortion is within the expected range for the general population. The interferons are assigned FDA Category C because of the risk of spontaneous abortion shown in animal studies whereas Copaxone is FDA Category B because animal studies have not shown adverse effects on fetal development, delivery, or infant growth. 01 04 03 Yoga and exercise help reduce fatigue in people with MS according to a 6-month 69-patient US study. The groups taking weekly Iyengar yoga classes adapted for people with MS or weekly exercise classes, also tailored to people with MS, showed significant improvement in their levels of fatigue. 08 04 03 Research compiled by: Tim Neale.